DODaniela Olivero

Daniela Olivero

*This is an algorithmically generated author record based on publicly available information.

Daniela Olivero has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reproductive conditioning of captive lionesses: Assessments of vaginal microbiota, oxidative stress and hormonal profile

    by Vincenzo Cicirelli, Matteo Burgio, Daniela Olivero, Pietro Laricchiuta, Giovanni Michele Lacalandra, Alice Carbonari, Stefano Carbonara, Annalisa Rizzo

  • Open Access

    Effects of Synbiotic Administration on Gut Microbiome and Fecal Bile Acids in Dogs with Chronic Hepatobiliary Disease: A Randomized Case–Control Study

    by Verena Habermaass, Corrado Biolatti, Francesco Bartoli, Eleonora Gori, Natascia Bruni, Daniela Olivero, Veronica Marchetti

    Alteration in the gut microbiome in human patients with chronic liver disease is a well-known pathophysiological mechanism. Therefore, it represents both a diagnostic and therapeutical target. Intestinal dysbiosis has also been identified in dogs with chronic liver disease, but clinical trials evaluating the effectiveness of synbiotic administration are lacking. Thirty-two dogs with chronic hepatobiliary disease were equally randomized into two groups: one treated with a synbiotic complex for 4–6 weeks (TG) and one untreated control group (CG). All dogs underwent clinical evaluation, complete anamnesis, bloodwork, abdominal ultrasound, fecal bile acids, and gut microbiome evaluation at T0–T1 (after 4–6 weeks). Treated dogs showed a significant reduction in ALT activity (p = 0.007) and clinical resolution of gastrointestinal signs (p = 0.026) compared to control dogs. The synbiotic treatment resulted in a lower increase in Enterobacteriaceae and Lachnospiraceae compared to the control group but did not affect the overall richness and number of bacterial species. No significant changes in fecal bile acids profile were detected with synbiotic administration. Further studies are needed to better evaluate the effectiveness of synbiotic administration in these patients and the metabolic pathways involved in determining the clinical and biochemical improvement.


  • Open Access

    Intestinal Microbiome in Dogs with Chronic Hepatobiliary Disease: Can We Talk about the Gut–Liver Axis?

    by Verena Habermaass, Daniela Olivero, Eleonora Gori, Chiara Mariti, Erika Longhi, Veronica Marchetti

    The gut–liver axis represents a current topic in human medicine. Extensive research investigates the gut microbiome (GM) modifications in relation to various kinds of chronic hepatobiliary diseases (CHD), with many mechanisms and therapeutical implications recognized. Those aspects in veterinary medicine are still quite unexplored. The aim of the present study was to evaluate GM in dogs diagnosed with CD. Comparison among CHD dogs were made considering some clinical and biochemical variables (lipemia and alanine–aminotransferase activities), presence of cholestasis or endocrine disorders, diet). Sixty-five dogs were prospectively enrolled with clinical and hematobiochemical evaluation and 16S-RNA GM sequencing assessed. Dogs that received antibiotics and/or pre/pro/symbiotics administration were excluded. Deeper GM alteration was observed between dogs with or without ultrasonographic and biochemical cholestatic CHD. Cholestasis was associated with a decrease in several bacterial taxa, including Clostridium hiranonis, Fusobacterium, Megamonas, Ruminococcus faecis, Turicibacter, and higher levels of Escherichia/Shigella and Serratia. Thus, the alteration in bile flow and composition, typical of cholestasis, may directly affect the local intestinal microbial environment. For the management of dogs with CHD and especially cholestatic CHD, clinicians should be aware that gut–liver interaction may lead to dysbiosis.


  • Open Access

    Polycomb group ring finger protein 6 suppresses Myc-induced lymphomagenesis

    by Nina Tanaskovic, Mattia Dalsass, Marco Filipuzzi, Giorgia Ceccotti, Alessandro Verrecchia, Paola Nicoli, Mirko Doni, Daniela Olivero, Diego Pasini, Haruhiko Koseki, et al.

    Max is an obligate dimerization partner for the Myc transcription factors and for several repressors, such as Mnt, Mxd1-4, and Mga, collectively thought to antagonize Myc function in transcription and oncogenesis. Mga, in particular, is part of the variant Polycomb group repressive complex PRC1.6. Here, we show that ablation of the distinct PRC1.6 subunit Pcgf6–but not Mga–accelerates Myc-induced lymphomagenesis in Eµ-myc transgenic mice. Unexpectedly, however, Pcgf6 loss shows no significant impact on transcriptional profiles, in neither pre-tumoral B-cells, nor lymphomas. Altogether, these data unravel an unforeseen, Mga- and PRC1.6-independent tumor suppressor activity of Pcgf6.


  • Open Access

    Polycomb Group Ring Finger Protein 6 suppresses Myc-induced lymphomagenesis

    by Nina Tanaskovic, Mattia Dalsass, Giorgia Ceccotti, Marco Filipuzzi, Alessandro Verrecchia, Paola Nicoli, Mirko Doni, Daniela Olivero, Diego Pasini, Haruhiko Koseki, et al.

    Max is an obligate dimerization partner for the Myc transcription factors and for several repressors, such as Mnt, Mxd1-4 and Mga, collectively thought to antagonize Myc function in transcription and oncogenesis. Mga, in particular, is part of the variant Polycomb group repressive complex PRC1.6. Here, we show that ablation of the distinct PRC1.6 subunit Pcgf6 – but not Mga – accelerates Myc-induced lymphomagenesis in Eµ- myc transgenic mice. Unexpectedly, however, Pcgf6 loss shows no significant impact on transcriptional profiles, in neither pre-tumoral B-cells, nor lymphomas. Altogether, these data unravel an unforeseen, Mga- and PRC1.6-independent tumor suppressor activity of Pcgf6.